AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the present application.

Listing of Claims

1. (currently amended) A compound of the structure:



(I)

or pharmaceutically acceptable salt, ester or salt of ester thereof;

wherein R_1 is hydrogen, aliphatic, heteroaliphatic, alicyclic or aryl;

R_2 ~~and~~ is methyl; R_3 ~~are each independently~~ is hydrogen~~,~~ or halogen~~, hydroxyl, protected hydroxyl, or an aliphatic, heteroaliphatic, alicyclic or aryl moiety; or~~

~~R_1 and R_2, when taken together, form a substituted or unsubstituted, saturated or unsaturated cyclic ring of 3 to 8 carbon atoms;~~

~~or R_1 and R_3, when taken together, form a substituted or unsubstituted, saturated or unsaturated cyclic ring of 3 to 8 carbon atoms~~;

R_4 is hydrogen or halogen;

R_5 is hydrogen or an oxygen protecting group;

R_6 is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R_7~~, for each occurrence,~~ is ~~independently~~ hydrogen~~, hydroxyl, or protected hydroxyl~~;

R_8 is hydrogen, halogen, hydroxyl, protected hydroxyl~~,~~ or alkyloxy~~, or an aliphatic moiety optionally substituted with hydroxyl, protected hydroxyl, SR_{12}, or $NR_{12}R_{13}$~~;

R_9 is $NR_{12}R_{13}$;

wherein R_{12} and R_{13} are, independently for each occurrence, hydrogen, aliphatic, heteroaliphatic, alicyclic or aryl; or a protecting group, and each of R_{12} and R_{13} are

optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,

R_{10} is ~~hydrogen,~~ hydroxyl, protected hydroxyl, or amino~~, or protected amino~~;

R_{11} is hydrogen~~, hydroxyl or protected hydroxyl~~;

X is ~~absent or is~~ O, NH, or N-alkyl~~, CH_2 or S~~;

Y is CHR_{17}, O, ~~C=O,~~ CR_{17} or NR_{17}; and Z is CHR_{18}, ~~O,~~ C=O, or CR_{18}~~ or NR_{18}~~, wherein each occurrence of R_{17} and R_{18} is ~~independently~~ hydrogen~~ or aliphatic~~, or R_{17} and R_{18} taken together is -O-, or $-CH_2-$ ~~or NR_{19}, wherein R_{19} is hydrogen or C_{1-6}alkyl~~, and Y and Z are connected by a single or double bond.

2. (canceled)

3. (currently amended) A compound of the structure:



(I)

or pharmaceutically acceptable salt, ester or salt of ester thereof;

wherein: R_1 is hydrogen, straight or branched C_{1-6}alkyl, straight or branched C_{1-6}heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;

R_2 is methyl; ~~and~~ R_3 ~~are each independently~~ is hydrogen~~,~~ or halogen~~, hydroxyl, protected hydroxyl, straight or branched C_{1-6}alkyl, straight or branched C_{1-6}heteroalkyl, or aryl,~~

~~wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or~~

~~R_1 and R_2, when taken together, form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or~~

~~R_1 and R_3, when taken together, form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen~~;

R_4 is hydrogen or halogen;

R_5 is hydrogen or a protecting group;

R_6 is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R_7~~, for each occurrence,~~ is ~~independently~~ hydrogen~~, hydroxyl, or protected hydroxyl~~;

R_8 is hydrogen, halogen, hydroxyl, protected hydroxyl, or alkyloxy~~, or C_{1-6}alkyl optionally substituted with hydroxyl, protected hydroxyl, SR_{12}, or $NR_{12}R_{13}$~~;

R_9 is $NR_{12}R_{13}$;

wherein R_{12} and R_{13} are, independently for each occurrence, hydrogen, C_{1-6}alkyl, aryl, alkylaryl, or a protecting group, and each of R_{12} and R_{13} are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,

R_{10} is ~~hydrogen,~~ hydroxyl, protected hydroxyl, or amino~~, or protected amino~~;

R_{11} is hydrogen~~, hydroxyl or protected hydroxyl~~;

X is ~~absent or is~~ O, NH, or N-alkyl~~, CH_2 or S~~;

Y is CHR_{17}, O, ~~C=O,~~ CR_{17} or NR_{17}; and Z is CHR_{18}, ~~O,~~ C=O, or CR_{18}~~ or NR_{18}~~, wherein each occurrence of R_{17} and R_{18} is ~~independently~~ hydrogen ~~or C_{1-6}alkyl,~~ or R_{17} and R_{18} taken together is -O-, or -CH_2~~ or NR_{19}, wherein R_{19} is hydrogen or C_{1-6}alkyl~~, and Y and Z are connected by a single or double bond.

4. (original) The compound of claim 3, where X is oxygen and n is 1.

5. (original) The compound of claim 3, where R_4 is halogen.

6. (original) The compound of claim 3, where R_4 is fluorine.

7. (original) The compound of claim 3, where Y and Z together represent -CH=CH-

8. (original) The compound of claim 3, where Y and Z together represent trans -CH=CH-.

9. (currently amended) The compound of claim 3, wherein R_1 ~~and R_2 are each~~ is methyl and R_3 is hydrogen and the compound is of the structure:



wherein R_4-R_{11}, n, X, Y and Z are as defined in claim 3.

10. (original) The compound of claim 9, wherein X is oxygen and n is 1.

11. (original) The compound of claim 9, wherein R_4 is halogen.

12. (original) The compound of claim 9, wherein Y and Z together represent -CH=CH.

13. (original) The compound of claim 9, wherein X is oxygen, n is 1, R_4 is halogen and Y and Z together represent -CH=CH-.

14. (original) The compound of claim 12 or 13 wherein -CH=CH- is trans.

15. (canceled)

16. (canceled)

17. (currently amended) The compound of claim ~~15~~ 3, wherein R_4 is ~~halogen~~ hydrogen.

18. (currently amended) The compound of claim ~~15~~ 17, wherein Y and Z together represent -CH=CH-.

19. (currently amended) The compound of claim ~~15~~17, wherein R_1 ~~and R_2 are each~~ is methyl and R_3 is hydrogen.

20. (currently amended) The compound of claim ~~15~~17, wherein X is oxygen, n is 1, R_1 ~~and R_2 are each~~ is methyl, R_3 is hydrogen, ~~R_4 is halogen,~~ and Y and Z together represent -CH=CH-.

21. (original) The compound of claim 18 or 20, wherein -CH=CH- is trans.

22. (previously presented) The compound of claim 1, wherein the compound is of the structure:


,

,

,

,

,

,

,

or pharmaceutically acceptable salt, ester or salt of ester thereof.

23-36. (canceled)

37. (currently amended) A pharmaceutical composition comprising:

a compound of any one of claims 1, 3, 9 and ~~15~~17; or pharmaceutically acceptable salt, ester or salt of ester thereof; and a pharmaceutically acceptable carrier.

38. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to inhibit NF-κB activation.

39-42. (canceled)

43. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to have an anti-inflammatory effect.

44. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to treat psoriasis.

45. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to reduce skin photodamage.

46-65. (canceled)

66. (previously presented) The pharmaceutical composition of claim 37 wherein the compound has the structure:



,


,


,


,


,


,



,

or pharmaceutically acceptable salt, ester or salt of ester thereof.

67-83. (canceled)

84. (withdrawn, currently amended) A method for treating an inflammatory and/or autoimmune disorder or a disorder resulting from increased angiogenesis and/or cell proliferation comprising:

administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1, 3, ~~9~~ 131 and ~~15~~ 132; and a pharmaceutically acceptable carrier or diluent.

85. (withdrawn) The method of claim 84, wherein the method is for treating a disorder selected from the group consisting of rheumatoid arthritis, psoriasis, asthma, cancer, sepsis, inflammatory bowel disease, atopic dermatitis, Crohn's disease, and autoimmune disorders.

86. (withdrawn) The method of claim 84, wherein the method is for treating rheumatoid arthritis.

87. (withdrawn) The method of claim 84, wherein the method is for treating psoriasis.

88. (withdrawn) The method of claim 84, wherein the method is for treating asthma.

89-107. (canceled)

108. (withdrawn, previously presented) The method of claim 84, wherein the compound is of the structure:


,

,

,

,

,

,

,

or pharmaceutically acceptable salt, ester or salt of ester thereof.

109-118. (canceled)

119. (withdrawn, currently amended) A method for providing protection against UVB-induced photodamage to a subject, said method comprising:

administering to the subject in need thereof a composition comprising a compound of ~~the structure:~~



~~(I)~~

claim 1~~or pharmaceutically acceptable salt, ester or salt of ester thereof;~~

~~wherein R_1 is hydrogen, straight or branched C_{1-6}alkyl, straight or branched C_{1-6}heteroalkyl, or aryl,~~

~~wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;~~

~~R_2 and R_3 are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched C_{1-6}alkyl, straight or branched C_{1-6}heteroalkyl, or aryl,~~

~~wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or~~

~~R_1 and R_2, when taken together, form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or~~

~~R_1 and R_3, when taken together, form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;~~

~~R_4 is hydrogen or halogen;~~

~~R_5 is hydrogen or an oxygen protecting group;~~

~~R_6 is hydrogen, hydroxyl, or protected hydroxyl;~~

~~n is 0-2;~~

~~R_7, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;~~

~~R_8 is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or C_{1-6}alkyl optionally substituted with hydroxyl, protected hydroxyl, SR_{12}, or $NR_{12}R_{13}$;~~

~~R_9 is $NR_{12}R_{13}$;~~

~~wherein R_{12} and R_{13} are, independently for each occurrence, hydrogen, C_{1-6}alkyl, aryl, alkylaryl, or a protecting group, and each of R_{12} and R_{13} are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,~~

~~R_{10} is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;~~

~~R_{11} is hydrogen, hydroxyl or protected hydroxyl;~~

~~X is absent or is O, NH, N-alkyl, CH_2 or S;~~

~~Y is CHR_{17}, O, C=O, CR_{17} or NR_{17}; and Z is CHR_{18}, O, C=O, CR_{18} or NR_{18}, wherein each occurrence of R_{17} and R_{18} is independently hydrogen or C_{1-6}alkyl, or R_{17} and R_{18} taken together is O, CH_2 or NR_{19}, wherein R_{19} is hydrogen or C_{1-6}alkyl, and Y and Z are connected by a single or double bond;~~ and

a pharmaceutically acceptable carrier or diluent.

120. (withdrawn) The method of claim 119, wherein in the step of administering, the composition is administered topically.

121. (withdrawn) The method of claim 119, wherein the photodamage is skin wrinkles.

122. (withdrawn) The method of claim 119, wherein the photodamage is a skin cancer.

123. (withdrawn, currently amended) A method for reducing the rate of restenosis, comprising:

inserting a stent into an obstructed blood vessel, the stent having a generally tubular structure, the surface of the structure being coated with (or otherwise adapted to release) a composition comprising a compound of ~~the structure:~~



~~(I)~~

claim 1~~or pharmaceutically acceptable salt, ester or salt of ester thereof;~~

~~wherein R_1 is hydrogen, straight or branched C_{1-6}alkyl, straight or branched C_{1-6}heteroalkyl, or aryl,~~

~~wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;~~

~~R_2 and R_3 are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched C_{1-6}alkyl, straight or branched C_{1-6}heteroalkyl, or aryl,~~

~~wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or~~

~~R_1 and R_2, when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or~~

~~R_1 and R_3, when taken together, form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;~~

~~R_4 is hydrogen or halogen;~~

~~R_5 is hydrogen or an oxygen protecting group;~~

~~R_6 is hydrogen, hydroxyl, or protected hydroxyl;~~

~~n is 0-2;~~

~~R_7, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;~~

~~R_8 is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or C_{1-6}alkyl optionally substituted with hydroxyl, protected hydroxyl, SR_{12}, or $NR_{12}R_{13}$;~~

~~R_9 is $NR_{12}R_{13}$;~~

~~wherein R_{12} and R_{13} are, independently for each occurrence, hydrogen, C_{1-6}alkyl, aryl, alkylaryl, or a protecting group, and each of R_{12} and R_{13} are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,~~

~~R_{10} is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;~~

~~R_{11} is hydrogen, hydroxyl or protected hydroxyl;~~

~~X is absent or is O, NH, N-alkyl, CH_2 or S;~~

~~Y is CHR_{17}, O, C=O, CR_{17} or NR_{17}; and Z is CHR_{18}, O, C=O, CR_{18} or NR_{18}, wherein each occurrence of R_{17} and R_{18} is independently hydrogen or C_{1-6}alkyl, or R_{17} and R_{18} taken together is =O, =CH_2 or =NR_{19}, wherein R_{19} is hydrogen or C_{1-6}alkyl, and Y and Z are connected by a single or double bond;~~ and optionally a pharmaceutically acceptable carrier or diluent;

such that the obstruction is eliminated and the composition is delivered in amounts effective to prevent or reduce the rate of restenosis.

124. (withdrawn, currently amended) A method for expanding the lumen of a body passageway, comprising:

inserting a stent into the passageway, the stent having a generally tubular structure, the surface of the structure being coated with (or otherwise adapted to release) a composition comprising a compound of ~~the structure:~~



~~(I)~~

claim 1 ~~or pharmaceutically acceptable salt, ester or salt of ester thereof;~~

~~wherein R_1 is hydrogen, straight or branched C_{1-6}alkyl, straight or branched C_{1-6}heteroalkyl, or aryl,~~

~~wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;~~

~~R_2 and R_3 are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched C_{1-6}alkyl, straight or branched C_{1-6}heteroalkyl, or aryl,~~

~~wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or~~

~~R_1 and R_2, when taken together, form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or~~

~~R_1 and R_3, when taken together, form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;~~

~~R_4 is hydrogen or halogen;~~

~~R_5 is hydrogen or a protecting group;~~

~~R_6 is hydrogen, hydroxyl, or protected hydroxyl;~~

~~n is 0-2;~~

~~R_7, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;~~

~~R_8 is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or C_{1-6}alkyl optionally substituted with hydroxyl, protected hydroxyl, SR_{12}, or $NR_{12}R_{13}$;~~

~~R_9 is $NR_{12}R_{13}$;~~

~~wherein R_{12} and R_{13} are, independently for each occurrence, hydrogen, C_{1-6}alkyl, aryl, alkylaryl, or a protecting group, and each of R_{12} and R_{13} are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,~~

~~R_{10} is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;~~

~~R_{11} is hydrogen, hydroxyl or protected hydroxyl;~~

~~X is absent or is O, NH, N-alkyl, CH_2 or S;~~

~~Y is CHR_{17}, O, C=O, CR_{17} or NR_{17}; and Z is CHR_{18}, O, C=O, CR_{18} or NR_{18}, wherein each occurrence of R_{17} and R_{18} is independently hydrogen or C_{1-6}alkyl, or R_{17} and R_{18} taken together is =O, $=CH_2$ or $=NR_{19}$, wherein R_{19} is hydrogen or C_{1-6}alkyl, and Y and Z are connected by a single or double bond;~~ and optionally a pharmaceutically acceptable carrier or diluent;

such that the passageway is expanded.

125. (withdrawn) The method of claim 124, wherein the lumen of a body passageway is expanded in order to eliminate a biliary, gastrointestinal, esophageal, tracheal/bronchial, urethral and/or vascular obstruction.

126. (withdrawn) The method of claim 125, wherein the lumen of a body passageway is expanded in order to eliminate a vascular obstruction.

127. (canceled)

128. (currently amended) A compound of claim ~~127~~21, wherein R_{12} is methyl, ethyl, propyl, isopropyl or butyl, optionally substituted with one or more occurrences of hydroxyl or protected hydroxyl and wherein R_{13} is hydrogen or C_{1-6}alkyl.

129. (previously presented) A compound of the formula:



or a pharmaceutically acceptable salt, ester or salt of ester thereof.

130. (previously presented) A compound of claim 129, wherein the compound is of the formula:



131. (previously presented) A compound of the formula:



or a pharmaceutically acceptable salt, ester or salt of ester thereof.

132. (previously presented) A compound of claim 131, wherein the compound is of the formula:



133. (withdrawn, new) The method of claim 119, said method comprising: administering to the subject in need thereof a composition comprising the compound of claims 3, 22, 131 and 132.

134. (withdrawn, new) The method of claim 123, said method comprising:

inserting a stent into an obstructed blood vessel, the stent having a generally tubular structure, the surface of the structure being coated with (or otherwise adapted to release) a composition comprising a compound of claims 3, 22, 131 and 132.

135. (withdrawn, new) The method of claim 124, said method comprising:
inserting a stent into the passageway, the stent having a generally tubular structure, the surface of the structure being coated with (or otherwise adapted to release) a composition comprising a compound of claims 3, 22, 131 and 132.